Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
Recruiting · NCT07383818 · Registry updated 2026-02-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-02-03 | NCT07383818 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| First Affiliated Hospital of Zhejiang University | 201 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Harbin Medical University Cancer Hospital | Harbin | China | 35 |
| The First Affiliated Hospital of Anhui Medical University | Hefei | China | 28 |
| The Second Affiliated Hospital of Xi'an Jiaotong University | Zhengzhou | China | 1 |
| The Second Affiliated Hospital of Xi'an Jiaotong University | Xi'an | China | 22 |
| Zhongshan Hospital, Fudan University | Shanghai | China | 37 |